| Previous close | 11.92 |
| Open | 11.92 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 30.00 |
| Expiry date | 2025-12-19 |
| Day's range | 11.92 - 11.92 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
PR NewswireInsmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International Conference Plenary Session
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that late-breaking data from the ARISE study of ARIKAYCE® (amikacin liposome inhalation suspension) were presented at the American Thoracic Society (ATS) 2024 International Conference in San Diego. Data from ARISE evaluating patients with newly diagnosed or recurrent nontuberculous mycobacterial (NTM) lung infection caused by Mycob
GuruFocus.comInsider Sale: Chief Medical Officer Martina Flammer Sells Shares of Insmed Inc (INSM)
On May 17, 2024, Martina Flammer, Chief Medical Officer of Insmed Inc (NASDAQ:INSM), sold 4,642 shares of the company.
Simply Wall St.Insmed Incorporated (NASDAQ:INSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
As you might know, Insmed Incorporated ( NASDAQ:INSM ) recently reported its quarterly numbers. The results weren't...
© 2024 Yahoo. All rights reserved.